| College Oak Nursing & Rehabilitation Center | |
| 4635 College Oak Drive, Sacramento, California 95841 | |
| (916) 481-7434 | |
| Name | College Oak Nursing & Rehabilitation Center |
|---|---|
| Location | 4635 College Oak Drive, Sacramento, California |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 120 |
| Occupancy Rate | 78.5% |
| Medicare ID (CCN) | 056158 |
| Legal Business Name | Spyglass, Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1629158597 |
| Organization Name | C.O.N.R., INC. |
| Address | 4635 College Oak Dr, Sacramento, CA 95841 |
| Phone Number | 916-481-7434 |
News Archive
With the help of a multidisciplinary register and questionnaire study, Finnish researchers showed that both the educational level and its occupational orientation predict the mother's smoking during early pregnancy.
Shanghai Biolaxy announced the Chinese State Food & Drug Administration (SFDA) has approved the investigational new drug application (IND) for its oral insulin project (Nodlin), an innovative insulin formulation to treat diabetes. This IND approval allows Biolaxy to initiate its first phase I clinical study.
Near-normal control of glucose beginning as soon as possible after diagnosis would greatly improve the long-term prognosis of type 1 diabetes, concludes a study published in the July 27, 2009, issue of the Archives of Internal Medicine, which updates information about the clinical course of type 1 diabetes.
Sorrento Therapeutics, Inc. and IGDRASOL announced today that clinical data for CynviloqTM, a non-biologic nanoparticle formulation of paclitaxel, plus gemcitabine was published for the upcoming Annual Meeting of the American Society of Clinical Oncology.
› Verified 6 days ago
| NPI Number | 1831651645 |
| Organization Name | SPYGLASS, LLC |
| Address | 4635 College Oak Dr, Sacramento, CA 95841 |
| Phone Number | 916-481-7434 |
News Archive
With the help of a multidisciplinary register and questionnaire study, Finnish researchers showed that both the educational level and its occupational orientation predict the mother's smoking during early pregnancy.
Shanghai Biolaxy announced the Chinese State Food & Drug Administration (SFDA) has approved the investigational new drug application (IND) for its oral insulin project (Nodlin), an innovative insulin formulation to treat diabetes. This IND approval allows Biolaxy to initiate its first phase I clinical study.
Near-normal control of glucose beginning as soon as possible after diagnosis would greatly improve the long-term prognosis of type 1 diabetes, concludes a study published in the July 27, 2009, issue of the Archives of Internal Medicine, which updates information about the clinical course of type 1 diabetes.
Sorrento Therapeutics, Inc. and IGDRASOL announced today that clinical data for CynviloqTM, a non-biologic nanoparticle formulation of paclitaxel, plus gemcitabine was published for the upcoming Annual Meeting of the American Society of Clinical Oncology.
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
With the help of a multidisciplinary register and questionnaire study, Finnish researchers showed that both the educational level and its occupational orientation predict the mother's smoking during early pregnancy.
Shanghai Biolaxy announced the Chinese State Food & Drug Administration (SFDA) has approved the investigational new drug application (IND) for its oral insulin project (Nodlin), an innovative insulin formulation to treat diabetes. This IND approval allows Biolaxy to initiate its first phase I clinical study.
Near-normal control of glucose beginning as soon as possible after diagnosis would greatly improve the long-term prognosis of type 1 diabetes, concludes a study published in the July 27, 2009, issue of the Archives of Internal Medicine, which updates information about the clinical course of type 1 diabetes.
Sorrento Therapeutics, Inc. and IGDRASOL announced today that clinical data for CynviloqTM, a non-biologic nanoparticle formulation of paclitaxel, plus gemcitabine was published for the upcoming Annual Meeting of the American Society of Clinical Oncology.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 11.84 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 9.09 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 42.59 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.93 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.6 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 2.38 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 0.28 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.72 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 9.57 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.17 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 16.03 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 8.8 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 3.57 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.26 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 86.14 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 95.65 | 82.93 |
News Archive
With the help of a multidisciplinary register and questionnaire study, Finnish researchers showed that both the educational level and its occupational orientation predict the mother's smoking during early pregnancy.
Shanghai Biolaxy announced the Chinese State Food & Drug Administration (SFDA) has approved the investigational new drug application (IND) for its oral insulin project (Nodlin), an innovative insulin formulation to treat diabetes. This IND approval allows Biolaxy to initiate its first phase I clinical study.
Near-normal control of glucose beginning as soon as possible after diagnosis would greatly improve the long-term prognosis of type 1 diabetes, concludes a study published in the July 27, 2009, issue of the Archives of Internal Medicine, which updates information about the clinical course of type 1 diabetes.
Sorrento Therapeutics, Inc. and IGDRASOL announced today that clinical data for CynviloqTM, a non-biologic nanoparticle formulation of paclitaxel, plus gemcitabine was published for the upcoming Annual Meeting of the American Society of Clinical Oncology.
› Verified 6 days ago
Sherwood Healthcare Center Location: 4700 Elvas Ave, Sacramento, California 95819 Phone: (916) 454-5752 | |
Saylor Lane Healthcare Center Location: 3500 Folsom Boulevard, Sacramento, California 95816 Phone: (916) 457-3500 | |
Arden Post Acute Rehab Location: 3400 Alta Arden Expressway, Sacramento, California 95825 Phone: (916) 481-5500 | |
Briarwood Post Acute Location: 5901 Lemon Hill Ave, Sacramento, California 95824 Phone: (916) 383-2741 |